elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q39262123-78A9A8CE-B344-458F-BA58-C01F55E7F231
Q39262123-78A9A8CE-B344-458F-BA58-C01F55E7F231
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39262123-78A9A8CE-B344-458F-BA58-C01F55E7F231
The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.
P2860
Q39262123-78A9A8CE-B344-458F-BA58-C01F55E7F231
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39262123-78A9A8CE-B344-458F-BA58-C01F55E7F231
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
37d0eb9f8ac56bae99e0f57eb3e2966039d2c01d
P2860
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis